Literature DB >> 22321471

Hepatic encephalopathy and health-related quality of life.

Giampaolo Bianchi1, Marco Giovagnoli, Anna Simona Sasdelli, Giulio Marchesini.   

Abstract

The impact of overt hepatic encephalopathy on health-related quality of life is well defined, but it remains to be demonstrated how much the presence of minimal hepatic encephalopathy (MHE) might impair patients' perceived health status. MHE reduces cognitive abilities, with specific impairment in manual abilities, which can lead to a depressed mood that impairs perceived health status. Therefore, all subjects with cirrhosis should be systematically screened for MHE by validated tools. Early detection and treatment is mandatory to improve the quality of life of patients with advanced cirrhosis, their social isolation, and their daily lives.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22321471     DOI: 10.1016/j.cld.2011.12.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  11 in total

Review 1.  Management of covert hepatic encephalopathy.

Authors:  Abhijeet Waghray; Nisheet Waghray; Kevin Mullen
Journal:  J Clin Exp Hepatol       Date:  2014-04-01

2.  Lower values of handgrip strength and adductor pollicis muscle thickness are associated with hepatic encephalopathy manifestations in cirrhotic patients.

Authors:  L Augusti; L C Franzoni; L A A Santos; T B Lima; M V Ietsugu; K H Koga; S M Moriguchi; L E Betting; C A Caramori; G F Silva; F G Romeiro
Journal:  Metab Brain Dis       Date:  2016-04-30       Impact factor: 3.584

Review 3.  Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?

Authors:  Lise Lotte Gluud; Gitte Dam; Mette Borre; Iñigo Les; Juan Cordoba; Giulio Marchesini; Niels Kristian Aagaard; Hendrik Vilstrup
Journal:  Metab Brain Dis       Date:  2012-12-29       Impact factor: 3.584

Review 4.  The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy.

Authors:  M M Lauridsen; M Thiele; N Kimer; H Vilstrup
Journal:  Metab Brain Dis       Date:  2013-01-10       Impact factor: 3.584

5.  Albumin therapy for hepatic encephalopathy: current evidence and controversies.

Authors:  Yu Jun Wong; Jing Hong Loo
Journal:  Metab Brain Dis       Date:  2022-05-26       Impact factor: 3.584

6.  Screening for minimal hepatic encephalopathy in patients with cirrhosis by cirrhosis-related symptoms and a history of overt hepatic encephalopathy.

Authors:  Emi Yoshimura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Naota Taura; Satoshi Miuma; Hidataka Shibata; Takuya Honda; Fuminao Takeshima; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2016-06-13

7.  Changes in sleep architecture and quality in minimal hepatic encephalopathy patients and relationship to psychological dysfunction.

Authors:  Changyun Liu; Jianguang Zhou; Xuedong Yang; Jiao Lv; Yunxing Shi; Xiaohong Zeng
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.

Authors:  Christian Schulz; Kerstin Schütte; Siegfried Kropf; Friedhelm C Schmitt; Riccardo Vasapolli; Leon M Kliegis; Antonia Riegger; Peter Malfertheiner
Journal:  Trials       Date:  2016-02-29       Impact factor: 2.279

9.  The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy.

Authors:  Rosalie C Oey; Lennart E M Buck; Nicole S Erler; Henk R van Buuren; Robert A de Man
Journal:  Therap Adv Gastroenterol       Date:  2019-06-23       Impact factor: 4.409

10.  GABA-A receptor modulating steroids in acute and chronic stress; relevance for cognition and dementia?

Authors:  S K S Bengtsson; T Bäckström; R Brinton; R W Irwin; M Johansson; J Sjöstedt; M D Wang
Journal:  Neurobiol Stress       Date:  2019-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.